Karolinska Development: Investing in innovative business




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Karolinska Development: Investing in innovative business
Released on: November 04, 2015. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Jim Van Heusden of Karolinska speaks to Fintan Walton of PharmaVentures about his strategy for the company’s growth, his ambitions for investment opportunities outside Sweden, and the challenges and benefits of rationalising the company’s portfolio.
  • Summary
  • Transcript
  • Participants
  • Company
Jim Van Heusden of Karolinska speaks to Fintan Walton of PharmaVentures about his strategy for the company’s growth, his ambitions for investment opportunities outside Sweden, and the challenges and benefits of rationalising the company’s portfolio. Karolinska Development is an investment fund that translates science into innovative businesses to facilitate new drug development and value for its shareholders. In the six months since being appointed CEO, Jim Van Heusden has refreshed Karolinska’s strategy, divesting several companies whilst securing annuities, and sourcing further investment for the retained core portfolio group.
Jim Van Heusden of Karolinska speaks to Fintan Walton of PharmaVentures about his strategy for the company’s growth, his ambitions for investment opportunities outside Sweden, and the challenges and benefits of rationalising the company’s portfolio. Karolinska Development is an investment fund that translates science into innovative businesses to facilitate new drug development and value for its shareholders. In the six months since being appointed CEO, Jim Van Heusden has refreshed Karolinska’s strategy, divesting several companies whilst securing annuities, and sourcing further investment for the retained core portfolio group.
Appointed in 2015. Born 1971. PhD. Jim Van heusden has over 20 years of experience within venture capital, research and development within the pharmaceutical industry, including as Founder and Managing Director at bioskills (2013-2015) and as Partner at the European investment company Gimv (2001-2013). During his appointment at Gimv he also served as a Board member in several biotech companies including Multiplicom NV (as Chairman), Ablynx NV, ActoGeniX NV, Pronota NV and Prosensa. During 1993-2001, Jim Van heusden worked as Senior Scientist at Janssen Pharmaceuticals (Johnson & Johnson). Holdings in Karolinska Development 93,668 shares.
Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.